215 related articles for article (PubMed ID: 20382692)
21. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
Iwasaki-Ishizuka Y; Yamato H; Nii-Kono T; Kurokawa K; Fukagawa M
Nephrol Dial Transplant; 2005 Sep; 20(9):1904-11. PubMed ID: 15985520
[TBL] [Abstract][Full Text] [Related]
22. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
Cantor T; Sci B
Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
[TBL] [Abstract][Full Text] [Related]
23. Is skeletal response to parathyroid hormone abnormal in experimental renal failure?
Patel S; Hsu CH
J Lab Clin Med; 1988 Sep; 112(3):387-93. PubMed ID: 3411200
[TBL] [Abstract][Full Text] [Related]
24. Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.
Herberth J; Branscum AJ; Mawad H; Cantor T; Monier-Faugere MC; Malluche HH
Am J Kidney Dis; 2010 May; 55(5):897-906. PubMed ID: 20347512
[TBL] [Abstract][Full Text] [Related]
25. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease.
Sawaya BP; Butros R; Naqvi S; Geng Z; Mawad H; Friedler R; Fanti P; Monier-Faugere MC; Malluche HH
Kidney Int; 2003 Aug; 64(2):737-42. PubMed ID: 12846773
[TBL] [Abstract][Full Text] [Related]
26. Circadian variation of mineral and bone parameters in end-stage renal disease.
Trivedi H; Szabo A; Zhao S; Cantor T; Raff H
J Nephrol; 2015 Jun; 28(3):351-9. PubMed ID: 25138650
[TBL] [Abstract][Full Text] [Related]
27. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.
Johansen KL; Chertow GM
J Ren Nutr; 2007 Sep; 17(5):305-13. PubMed ID: 17720099
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D compounds for people with chronic kidney disease not requiring dialysis.
Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
Cochrane Database Syst Rev; 2009 Oct; (4):CD008175. PubMed ID: 19821446
[TBL] [Abstract][Full Text] [Related]
29. Sequential changes of biochemical bone parameters after kidney transplantation.
Reinhardt W; Bartelworth H; Jockenhövel F; Schmidt-Gayk H; Witzke O; Wagner K; Heemann UW; Reinwein D; Philipp T; Mann K
Nephrol Dial Transplant; 1998 Feb; 13(2):436-42. PubMed ID: 9509459
[TBL] [Abstract][Full Text] [Related]
30. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
Parfitt AM
Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
32. Serum phosphorus adds to value of serum parathyroid hormone for assessment of bone turnover in renal osteodystrophy.
Gentry J; Webb J; Davenport D; Malluche HH
Clin Nephrol; 2016 Jul; 86(7):9-17. PubMed ID: 27191663
[TBL] [Abstract][Full Text] [Related]
33. Reversal of adynamic bone disease by lowering of dialysate calcium.
Haris A; Sherrard DJ; Hercz G
Kidney Int; 2006 Sep; 70(5):931-7. PubMed ID: 16837920
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
35. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
[TBL] [Abstract][Full Text] [Related]
36. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
37. Relationships between calcium and phosphorus homeostasis, parathyroid hormone levels, bone aluminum, and bone histomorphometry in patients on maintenance hemodialysis.
Nilsson P; Melsen F; Malmaeus J; Danielson BG; Mosekilde L
Bone; 1985; 6(1):21-7. PubMed ID: 2581596
[TBL] [Abstract][Full Text] [Related]
38. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients.
Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP
Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896
[TBL] [Abstract][Full Text] [Related]
39. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.
Mathias R; Salusky I; Harman W; Paredes A; Emans J; Segre G; Goodman W
J Am Soc Nephrol; 1993 Jun; 3(12):1938-46. PubMed ID: 8338926
[TBL] [Abstract][Full Text] [Related]
40. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
Slatopolsky EA; Burke SK; Dillon MA
Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
